La Jolla Pharmaceutical Company was granted Breakthrough Therapy designation by the FDA for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria.
The FDA’s Breakthrough Device designation is granted for technologies that have the potential to provide for more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases